3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Gynecologic
2
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Ovarian Neoplasms
10
Fallopian Tube Neoplasms
10
Prostatic Neoplasms
7
Carcinoma, Ovarian Epithelial
6
Endometrial Neoplasms
5
Breast Neoplasms
5
Recurrence
3
Pancreatic Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Triple Negative Breast Neoplasms
2
Small Cell Lung Carcinoma
2
Neoplasm Metastasis
2
Metastatic Castration Resistant Prostate Cancer
2
Lung Neoplasms
2
Carcinoma, Transitional Cell
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Prostate Cancer Metastatic
1
Primary Myelofibrosis
1
Pathologic Complete Response
1
Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Mental Retardation, X-Linked, With Or Without Seizures, Arx-Related
1
Interventions
Cisplatin
32
human papillomavirus vaccine, L1 type 16, 18
16
Brachytherapy
15
Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
12
Paclitaxel
11
Bevacizumab
11
pembrolizumab
10
Platinum
9
1,2-diaminocyclohexaneplatinum II citrate
9
Topotecan
8
Radiotherapy, Intensity-Modulated
8
Radiation
8
Papillomavirus Vaccines
8
atezolizumab
6
Gemcitabine
6
Fluorodeoxyglucose F18
6
Cyclophosphamide
6
tisotumab vedotin
5
fludarabine phosphate
5
fludarabine
5
aldesleukin
5
Taxes
5
Radiotherapy
5
Magnetic Resonance Spectroscopy
5
Carboplatin
5
Vaccines, Synthetic
4
Nivolumab
4
Immunoglobulin G
4
Disulfides
4
Colposcopy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has results
×
Uterine Cervical Neoplasms
×
rucaparib
×
Clear all
NCT03476798
2024-02-15
Clovis-001
University of Oklahoma
Phase 2
Completed
49 enrolled
13 charts
NCT04171700
2023-10-02
LODESTAR
pharmaand GmbH
Phase 2
Terminated
83 enrolled
16 charts